Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Receivables for 5 consecutive years, with $2.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Receivables rose 290.32% to $2.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $2.1 million, a 290.32% increase, with the full-year FY2024 number at $2.1 million, up 290.32% from a year prior.
  • Receivables was $2.1 million for Q4 2024 at Fulcrum Therapeutics, up from $537000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.6 million in Q4 2021 to a low of $229000.0 in Q4 2022.
  • A 5-year average of $1.3 million and a median of $802500.0 in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 93.7% in 2022, then skyrocketed 290.32% in 2024.
  • Fulcrum Therapeutics' Receivables stood at $2.5 million in 2020, then surged by 43.7% to $3.6 million in 2021, then tumbled by 93.7% to $229000.0 in 2022, then skyrocketed by 134.5% to $537000.0 in 2023, then surged by 290.32% to $2.1 million in 2024.
  • Per Business Quant, the three most recent readings for FULC's Receivables are $2.1 million (Q4 2024), $537000.0 (Q4 2023), and $580000.0 (Q3 2023).